Octreotide Therapy in Asparaginase-Associated Pancreatitis in Childhood Acute Lymphoblastic Leukemia

ASIAIR > College of Medical and Health Science > Department of Biotechnology > Journal Article > Item 310904400/8319

Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/8319

Title:	Octreotide Therapy in Asparaginase-Associated Pancreatitis in Childhood Acute Lymphoblastic Leukemia
Authors:	Wu, SF (Wu, Shu-Fen);Chen, AC (Chen, An-Chyi);Peng, CT (Peng, Ching-Tien);Wu, KH (Wu, Kang-Hsi)
Contributors:	Department of Biotechnology
Keywords:	acute lymphoblastic leukemia;L-asparaginase;octreotide;pancreatitis；SOMATOSTATIN;TRIAL
Date:	2008-12
Issue Date:	2010-03-26 02:29:47 (UTC+0)
Publisher:	Asia University
Abstract:	Little is known about octreotide therapy in asparaginase-associated pancreatitis (AAP) in children. Of the 59 children with acute lymphoblastic leukemia (ALL) receiving E. Coli L-asparaginase, 5 patients (8.5%) developed AAP. Octreotide was administered to four patients. Clinical and laboratory improvement were evident after octreotide therapy. There were no deaths and no severe adverse side effects were noted. No pseudocysts were detected; however, two of the four patients developed diabetes. One child without octreotide treatment developed chronic pancreatitis and pseudocyst. We conclude that octreotide therapy appears to be safe and potentially beneficial in the management of AAP in children.
Relation:	PEDIATRIC BLOOD & CANCER 51 (6): 824-825
Appears in Collections:	[Department of Biotechnology] Journal Article

Files in This Item:

File	Description	Size	Format
214.doc		35Kb	Microsoft Word	199	View/Open
index.html		0Kb	HTML	432	View/Open